Skip to content
Putting Americans First: International prices in context
It is often taken as a given that drug prices in the U.S. are higher than those in other nations. And while there is […]
Putting Americans First: International prices in context Read More »
Health
BIO’s Texas visit will highlight a growing biotech ecosystem
Already providing employment for 129,245 people and $95 billion in annual economic output, Texas’s biotech sector is growing rapidly. That sector will be highlighted
BIO’s Texas visit will highlight a growing biotech ecosystem Read More »
Putting Americans First: No medicine is more expensive than the one patients can’t access
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the
BIO Coffee Chat looks at patient access after three years of the IRA
It has been three years since the Inflation Reduction Act (IRA) was signed into law. “We have definitively seen negative impacts on patient access,
BIO Coffee Chat looks at patient access after three years of the IRA Read More »
Riboway Therapeutics: Resilience, RNA, and redefining the undruggable
At this year’s BIO International Convention in Boston, Riboway Therapeutics emerged as the winner of the 2025 BIO Start-Up Stadium seed-stage category. For founder and
Riboway Therapeutics: Resilience, RNA, and redefining the undruggable Read More »
Startup Stadium: Tezcat Biosciences targets common cancer mutation
A Rat sarcoma (RAS) mutation is an oncogene, a gene that causes cancer when mutated. The RAS is the most commonly mutated oncogene in
Startup Stadium: Tezcat Biosciences targets common cancer mutation Read More »
Psoriasis awareness: The condition is more than skin deep
Over 8 million people in the U.S., and 125 million worldwide, live with psoriasis—about 2–3% of the population. Far from being a simple cosmetic
Psoriasis awareness: The condition is more than skin deep Read More »
BIO 2025: As M&A slows, biotechs need to show good data
M&A in biotech has slowed from its peak in 2023 but there are still deals to be done, especially for companies who can present
BIO 2025: As M&A slows, biotechs need to show good data Read More »
BIO 2025: How weight loss drugs are disrupting chronic disease
“Initial weight loss is just the first chapter,” said Mia de Graaf, Deputy Executive Health Editor at Business Insider, “but the real challenge and
BIO 2025: How weight loss drugs are disrupting chronic disease Read More »
BIO 2025: Psychedelics go mainstream – what’s next?
When experts discussed clinical uses of psychedelics two years ago at the 2023 Biotechnology Innovation Organization (BIO) International Convention, there was some interest in
BIO 2025: Psychedelics go mainstream – what’s next? Read More »